Nabriva Therapeutics plc (NBRV) Financial Statements (2024 and earlier)

Company Profile

Business Address 25-28 NORTH WALL QUAY
DUBLIN, D01 H104
State of Incorp.
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

6/30/2023
MRQ
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:12,41447,90041,60086,600102,20086,900
Cash and cash equivalents12,41447,65941,35986,019102,00386,769
Short-term investments  1616175225110
Other undisclosed cash, cash equivalents, and short-term investments  225225406(28)21
Receivables 3,9969,3211751,2143,8715,402
Inventory, net of allowances, customer advances and progress billings 9,67614,5095,823682  
Inventory 9,67614,5095,823682  
Prepaid expense2,1495,1555,8801,1581,1541,558
Contract with customer, asset, after allowance for credit loss     1,500
Other undisclosed current assets2,8693,3803,7401,51628(21)
Total current assets:31,10480,26557,21891,170108,75393,839
Noncurrent Assets
Nontrade receivables   370378428425
Property, plant and equipment2802337682,4741,1391,327
Intangible assets, net (including goodwill)331809198172
Intangible assets, net (excluding goodwill)331809198172
Other noncurrent assets378380    
Total noncurrent assets:6616441,2182,9431,6651,924
TOTAL ASSETS:31,76580,90958,43694,113110,41895,763
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities22,77218,20115,73316,63917,80613,260
Accounts payable5,4314,3722,8894,6733,3045,136
Accrued liabilities17,34113,82912,84411,96614,5028,124
Deferred revenue  374750 
Debt4,8333,7652,041   
Total current liabilities:27,60522,34018,52416,63917,80613,260
Noncurrent Liabilities
Long-term debt and lease obligation3884,2655,68634,50223,718232
Long-term debt, excluding current maturities3884,2655,68634,50223,718232
Liabilities, other than long-term debt4799541,0911,698264203
Other liabilities4799541,0911,698264203
Total noncurrent liabilities:8675,2196,77736,20023,982435
Total liabilities:28,47227,55925,30152,83941,78813,695
Equity
Equity, attributable to parent, including:3,29353,35033,13541,27468,63082,068
Common stock32567211945670 
Additional paid in capital656,095648,432579,123517,044461,911360,872
Accumulated other comprehensive income272727272727
Accumulated deficit(652,861)(595,676)(546,226)(476,742)(393,978)(279,198)
Other undisclosed equity, attributable to parent      367
Total equity:3,29353,35033,13541,27468,63082,068
TOTAL LIABILITIES AND EQUITY:31,76580,90958,43694,113110,41895,763

Income Statement (P&L) ($ in thousands)

6/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Revenues36,93528,8955,0279,4819,6565,319
Revenue, net5,319
Cost of revenue(28,581)(13,148)(766)(70)  
Cost of goods and services sold   (766)(70)  
Gross profit:8,35415,7474,2619,4119,6565,319
Operating expenses(59,527)(64,275)(70,387)(88,900)(124,031)(79,087)
Other undisclosed operating loss(4,317)     
Operating loss:(55,490)(48,528)(66,126)(79,489)(114,375)(73,768)
Nonoperating income (expense)5714691,273470(223)492
Investment income, nonoperating   8625549318
Other nonoperating income (expense)5714691,187215(272) 
Interest and debt expense (698)(901)(4,492)(3,644)(133)(43)
Other undisclosed loss from continuing operations before equity method investments, income taxes      
Loss from continuing operations before equity method investments, income taxes:(55,617)(48,960)(69,345)(82,663)(114,731)(73,319)
Other undisclosed income from continuing operations before income taxes     318
Loss from continuing operations before income taxes:(55,617)(48,960)(69,345)(82,663)(114,731)(73,001)
Income tax expense(1,568)(490)(139)(101)(49)(1,355)
Loss from continuing operations:(57,185)(49,450)(69,484)(82,764)(114,780)(74,356)
Loss before gain (loss) on sale of properties:(49,450)(69,484)(82,764)(114,780)(74,356)
Net loss available to common stockholders, diluted:(57,185)(49,450)(69,484)(82,764)(114,780)(74,356)

Comprehensive Income ($ in thousands)

6/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net loss:(57,185)(49,450)(69,484)(82,764)(114,780)(74,356)
Other comprehensive income      17
Comprehensive loss, net of tax, attributable to parent:(57,185)(49,450)(69,484)(82,764)(114,780)(74,339)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: